A patient at high fracture risk has completed four years of denosumab 60 mg every 6 months with good adherence and no adverse effect. Which long-term

Question

A patient at high fracture risk has completed four years of denosumab 60 mg every 6 months with good adherence and no adverse effect. Which long-term prescribing principle is correct?

Accepted Answer

Review benefit and risk, especially after 5 years; avoid a routine holiday

Answer

Continue 60 mg every 6 months without a scheduled risk review

Answer

Reduce to 30 mg every 6 months when treatment reaches year 5

Answer

Extend to 60 mg every 12 months when bone density has improved

Answer

Stop at year 5 and use a six-month holiday before reassessing treatment

Pathergy Test Behcet — SCE Rheumatology MCQ

A patient at high fracture risk has completed four years of denosumab 60 mg every 6 months with good adherence and no adverse effect. Which long-term prescribing principle is correct?